Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of NASDAQ TTNP opened at $5.26 on Thursday. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $13.97. The stock’s 50 day simple moving average is $6.56 and its 200 day simple moving average is $6.82.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.